PMID- 38250890
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240129
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 12
IP  - 1
DP  - 2024 Jan 12
TI  - A Mixture of T-Cell Epitope Peptides Derived from Human Respiratory Syncytial 
      Virus F Protein Conferred Protection in DR1-TCR Tg Mice.
LID - 10.3390/vaccines12010077 [doi]
LID - 77
AB  - Human respiratory syncytial virus (HRSV) poses a significant disease burden on 
      global health. To date, two vaccines that primarily induce humoral immunity to 
      prevent HRSV infection have been approved, whereas vaccines that primarily induce 
      T-cell immunity have not yet been well-represented. To address this gap, 25 
      predicted T-cell epitope peptides derived from the HRSV fusion protein with high 
      human leukocyte antigen (HLA) binding potential were synthesized, and their 
      ability to be recognized by PBMC from previously infected HRSV cases was assessed 
      using an ELISpot assay. Finally, nine T-cell epitope peptides were selected, each 
      of which was recognized by at least 20% of different donors' PBMC as potential 
      vaccine candidates to prevent HRSV infection. The protective efficacy of F-9PV, a 
      combination of nine peptides along with CpG-ODN and aluminum phosphate (Al) 
      adjuvants, was validated in both HLA-humanized mice (DR1-TCR transgenic mice, Tg 
      mice) and wild-type (WT) mice. The results show that F-9PV significantly enhanced 
      protection against viral challenge as evidenced by reductions in viral load and 
      pathological lesions in mice lungs. In addition, F-9PV elicits robust Th1-biased 
      response, thereby mitigating the potential safety risk of Th2-induced respiratory 
      disease during HRSV infection. Compared to WT mice, the F-9PV mice exhibited 
      superior protection and immunogenicity in Tg mice, underscoring the specificity 
      for human HLA. Overall, our results demonstrate that T-cell epitope peptides 
      provide protection against HRSV infection in animal models even in the absence of 
      neutralizing antibodies, indicating the feasibility of developing an HRSV T-cell 
      epitope peptide-based vaccine.
FAU - Guo, Hong
AU  - Guo H
AUID- ORCID: 0009-0000-9826-4044
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Song, Yang
AU  - Song Y
AUID- ORCID: 0000-0002-7053-3836
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Li, Hai
AU  - Li H
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Hu, Hongqiao
AU  - Hu H
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Shi, Yuqing
AU  - Shi Y
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Jiang, Jie
AU  - Jiang J
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Guo, Jinyuan
AU  - Guo J
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Cao, Lei
AU  - Cao L
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Mao, Naiying
AU  - Mao N
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for 
      Viral Disease Control and Prevention, Chinese Center for Disease Control and 
      Prevention, Beijing 102206, China.
AD  - National Key Laboratory of Intelligent Tracking and Forecasting for Infectious 
      Diseases (NITFID), National Institute for Viral Disease Control and Prevention, 
      Chinese Center for Disease Control and Prevention, Beijing 102206, China.
LA  - eng
PT  - Journal Article
DEP - 20240112
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC10820450
OTO - NOTNLM
OT  - T-cell epitope
OT  - human respiratory syncytial virus
OT  - peptide vaccine
COIS- We do not have conflicts of interest associated with this publication, and there 
      has been no financial support for this work that could have influenced its 
      outcome. This manuscript is original, has not been previously published, and is 
      not currently under consideration by another journal.
EDAT- 2024/01/22 06:42
MHDA- 2024/01/22 06:43
PMCR- 2024/01/12
CRDT- 2024/01/22 05:35
PHST- 2023/12/08 00:00 [received]
PHST- 2024/01/04 00:00 [revised]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/01/22 06:43 [medline]
PHST- 2024/01/22 06:42 [pubmed]
PHST- 2024/01/22 05:35 [entrez]
PHST- 2024/01/12 00:00 [pmc-release]
AID - vaccines12010077 [pii]
AID - vaccines-12-00077 [pii]
AID - 10.3390/vaccines12010077 [doi]
PST - epublish
SO  - Vaccines (Basel). 2024 Jan 12;12(1):77. doi: 10.3390/vaccines12010077.